Fennec Pharmaceuticals Posts Record Sales, 50% Annual Growth, and Completes $42M Equity Offering
FENC sits 57% above its 52-week low of $4.68.
Summary
Fennec Pharmaceuticals reported record full-year 2025 net PEDMARK® product sales of $44.6 million, representing 50% year-over-year growth, with Q4 2025 net product sales reaching $13.8 million, a 75% increase over Q4 2024. The company also announced the completion of an oversubscribed $42 million equity offering and positive topline results from an investigator-initiated clinical study of PEDMARK® in Japan. This news follows a recent 8-K filing regarding a patent litigation settlement, but these financial and business updates are new and distinct. The strong revenue growth figures demonstrate accelerating adoption of PEDMARK® and effective execution, which is highly positive for a company of Fennec's size. The $42 million equity offering significantly strengthens its financial position, providing capital for continued growth and development. Positive clinical data and new study initiations further de-risk the product and expand its potential market. Traders will monitor continued PEDMARK® sales trajectory, progress on the new clinical studies, and any further updates on market expansion or regulatory milestones.
At the time of this announcement, FENC was trading at $7.35 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $254.3M. The 52-week trading range was $4.68 to $9.92. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.